A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US) - SKOPOS:MAZI

Exclusion Criteria

• -Age <40 at time of treatment initiation
• -Invalid or unknown gender
• -If death date occurs prior to or on study index date
• -<12 months (365 days) of medical and pharmacy health plan eligibility/coverage prior treatment initiation
• -Presence of ≥1 prescription claim for any triple therapy during the patient’s entire available baseline history (BGF, FF/UMEC/VI or MITT)
• -“potential MITT use” in baseline, MITT for baseline purposes will be defined as ≥1 days continuous days where all three MITT components (ICS, LABA, LAMA) are observed in combination (dual + monotherapy) or as three separate monotherapy components
• -History of any of the following conditions, procedures or events during the immediate baseline 12-month period: (a) ≥1 medical claim (i.e., office, ED or hospital) in any position with a diagnosis for alpha-1-antitrypsin deficiency, interstitial fibrosis, lung cancer, pulmonary embolism, sarcoidosis; (b) ≥1 medical claim for hospice services; (c) Any medical Bill Type Code (BILL_TYPE_CODE ) starting with 81 or 82; or Revenue codes (RVNU_CD): 0651-0659; (d) ≥1 medical claim with a diagnosis code of encounter related to clinical trial participation (Z00.6) at any point during the study period (including both baseline and follow-up periods)